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1.1 INTRODUCTION 
 
Allergic rhinitis (AR) is the most common form of non-infectious rhinitis defined by an 
allergen-induce IgE-mediated inflammation of the nasal mucosa.1 Thought to occur after 
exposure to indoor and outdoor allergens such as house dust mite, insects, animal dander, 
molds and pollen. Patients usually presented with  cardinal symptoms of  rhinorrhea, sneezing, 
nasal itchiness and nasal blockage. AR involved in the cascade of inflammatory reaction 
whereby the initial exposure to allergens will produce an early response within minutes. At this 
phase, inflammatory mediators will cause mucosa edema leads to nasal congestion, rhinorhea 
and also stimulation of sensory nerve cause reflexes sneezing. The late phase response occurs 
after 4-8 hours of exposure to allergens. The cells mediated inflammatory reaction will be 
activated and nasal congestion will be prominent at this stage.  Cytokines produce during this 
phase can be reduced by glucocorticoids.  
AR can be classified according to its duration and severity. Persistent AR is when the patient 
experience symptoms at least 4 days a week and for at least 4 weeks while  intermittent AR is 
when the symptoms are present less than 4 days a week or for less than 4 weeks.  According to 
severity it can be divided into mild and  moderate-severe. In mild AR, none of these criteria of 
sleep disturbance, impairment of daily activities, leisure and/or sport, impairment of school or 
work or troublesome symptoms while in moderate to severe AR, at least 1 of the criteria 
present.2 
The prevalence of AR is about 10-20% of the population. In Malaysia, about 20-48.9% of 
patients suffering from moderate to severe persistent allergic rhinitis.3 
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 Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines have been widely used to treat 
approximately 500 million affected patients globally.  
According to this guideline, the mainstay treatment for moderate to severe persistent AR are 
intranasal corticosteroid and oral antihistamine. Pharmacologically, intranasal corticosteroids 
act by binding to endogenous corticosteroids receptors that involved in the inflammatory 
process, thus increase the synthesis of anti-inflammatory mediators and reduce the synthesis of 
proinflammatory mediators. It is effective against all symptoms of AR. Meanwhile, oral H1-
antihistamines acts by blocking the histamine receptors and are effective against symptoms 
mediated by histamine (rhinorrhea, sneezing, nasal itching and eye symptoms) but are less 
effective for nasal congestion. 
 
As compared to oral antihistamine, intranasal corticosteroids are more effective in view of high 
local drug concentration and minimal systemic bioavailability.4 
Few studies have been done to complement this standard treatment to improve management of 
AR in term of quality of life as well as economically.5,12 
 
However, none of the study used honey in the form of nasal spray for alternative treatment of 
AR. Honey nasal spray is the best way of administration to achieve the higher local effect. 
Thus, this study is conducted with the aim to assess the efficacy of Tualang honey nasal spray 
as adjunctive treatment of moderate to severe AR.  
 
Honey has been widely used as a food supplement as well as natural remedies since ancient 
time. The composition as well as physical properties of each honey will be differ according to 
the botanical and geographical origin.Various studies have been done to analyse the 
physiochemical properties of various types of honey in Malaysia and amongst them, Tualang 
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honey has a higher phenolic and flavonoid content that possesses the antioxidant properties. 
6,7,8 
A review article by Vallianouet et al, General Med, 2014 on honey showed that anti-
inflammatory and antioxidant properties of honey is from its bioactive substances of phenol 
and flavonoids.9 Among various types of Malaysian honey, Tualang honey has been shown to 
have high phenolic.10 
   
The anti-inflammatory effect of Tualang honey has been studied by Kamaruzaman et al. They 
investigated the effect of aerosolized honey (25% and 50% diluted) as an agent to alleviate the 
asthma-related histopathological changes that occur in the rabbit airway following ovalbumin 
(OVA)-induce airway inflammation. They demonstrated that treatment of aerosolized honey is 
effectively inhibited (OVA)-induced airway inflammation by alleviating asthma-related 
histopathological changes in the airway and also prevented occurrence of asthma.11 
 
Another study done by Zamzil Amin et al, comparing the outcome between placebo and 
ingestion of honey to improve the symptoms of allergic rhinitis found that there are significant 
improvements in 4 cardinal symptoms of AR in patients who ingested honey and the 
improvement persist for 1 month after cessation of the treatment.12 
 
Farnaz Hashemaian and colleagues from Hamadan University of Medical Science, Iran, did a 
study on effect of thyme honey nasal spray on chronic rhinosinusitis. It is a double-blind 
randomized controlled clinical trial comparing the outcome of treatment of post FESS patients 
with thyme honey nasal spray and placebo as adjunct to fluticasone nasal spray. They found  
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that trial group who received honey nasal spray showed significant improvement decrease in 
endoscopic scores as compared to those received placebo as an adjunct.13 
Beside its anti- inflammatory properties, Tualang honey also has antibacterial effect. Nasir et 
al found that tualang honey has bacteriostatic and bactericidal effects and can be use as dressing 
for burn wound.15 
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2.0   STUDY OBJECTIVES 
2.1  General objectives 
To evaluate the effectiveness of honey nasal spray as an adjunct treatment in patient with 
moderate to severe persistent allergic rhinitis. 
 
2.1  Specific objectives 
1. To evaluate the mean total SNOT-22 score between control and trial group at 
baseline, 2nd and 6th weeks of treatment. 
2. To evaluate  the mean symptoms score (rhinorrhea, nasal blockage & sneezing) 
between control and trial group at baseline,  2nd  and 6th  weeks of treatment. 
3. To evaluate  the total serum IgE level between control and trial group at baseline 
and 6th weeks of treatment. 
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3.2 ABSTRACT 
BACKGROUND  
Allergic rhinitis is an IgE-mediated inflammation of the nasal mucosa. The management of 
allergic rhinitis has not changed much and only limited studies has been done to explore the 
benefit of complementary alternative therapy. Honey is proven in its anti-inflammatory, anti-
bacterial and anti-oxidant properties and found to be useful for treatment of inflammation. We 
aimed to determine the efficacy of honey nasal spray as an adjunct treatment of moderate to 
severe persistent allergic rhinitis. 
 
METHOD  
Patients were recruited from our Otorhinolaryngology- Head & Neck Surgery Clinic from 
November 2015 to July 2016. Thirty moderate to severe persistent allergic rhinitis patients with 
positive skin prick tests were divided randomly into control and trial group. Both groups 
received standard medication (intranasal corticosteroids and oral antihistamines). In addition, 
the trial group received honey nasal spray as adjunctive daily dose. Patients were assessed 
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using SNOT22 questionnaires at 0, 2nd  and 6th weeks of the study with the focus on the primary 
symptoms of nasal blockage, rhinorrhea and sneezing 
 
RESULTS  
There was overall improvement of total SNOT 22 score and each symptom score of nasal 
blockage, rhinorrhea and sneezing together with the total serum IgE level in both groups at the 
end of 6 weeks. However, the improvement was seen more consistently in the trial group as 
evidenced by the reduction of estimated means score of all measured outcomes. 
 
CONCLUSION  
The honey nasal spray has beneficial effect as an adjunct treatment in moderate to severe 
persistent allergic rhinitis by acting as a protective mucous layer in reducing the attachment of 
allergen to the nasal mucosa.  
 
Keywords: Honey; Topical nasal spray; Allergic rhinitis 
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3.3 INTRODUCTION  
Allergies in Asia-Pacific Survey found that the overall prevalence of allergic rhinitis (AR) 
among Asian was 8.7 %.1 This will continue to increase in view of rapid economic development 
and urbanization. Asha’ari et al2 found that 20-48.9% of patients suffering from moderate to 
severe persistent AR in Malaysia. In patients with AR, exposure to allergens will produce an 
early response within minutes which results  in a cascade of inflammatory reaction. 
Inflammatory mediators will cause mucosa edema that leads to nasal congestion, rhinorhea and 
also stimulation of sensory nerve which causes reflex sneezing. The late phase response occurs 
after four to eight hours of exposure to allergens. The cells mediated inflammatory reaction 
will be activated and nasal congestion will be prominent at this stage.3 
As proposed by ARIA guidelines 2007, the standard treatment for moderate to severe persistent 
AR are intranasal corticosteroids (INS) and oral antihistamine.4 Both acts by reducing the 
inflammatory reaction in AR. From our observation, we found that, many of our patients were 
dependent on the medications despite compliant because we cannot step down the medications. 
This probably due to continuous allergen  exposure. 
With prolonged use of intranasal corticosteroid, the patients are more concerned on its side 
effects. Growth retardation, thinning of the skin and osteoporosis is the well known systemic 
side effects of steroid. Even though intranasal corticosteroid has lower systemic bioavailabity 
as compare to inhaled corticosteroid, systemic side effect such as suppression of hypothalamic-
pituitary axis (HPA)  and growth retardation has been reported in children with prolonged use 
of INS.5  However, local side effects are commonly experienced by patients who received  long 
term INS such as epistaxis, dryness and crusting of the nasal mucosa.6 
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Oral antihistamine meanwhile, has its systemic side effect which is contributed by its sedative 
action, such as drowsiness and CNS depressant. Other than that, it also has a relative risk of 
cardiotoxicity.7 The sedative effect might impair patient’s school and work performance as 
well as quality of life. 
Concerned with the above matter, we conducted a study on topical use of honey in allergic 
rhinitis to minimize the treatment of AR. 
Honey has an anti-inflammatory property and is widely used in studies conducted to 
complement the conventional treatment in AR. However, at which level of inflammatory 
processes that is blocked by honey is unknown. Honey also has been recognized to have 
immunomodulatory property and the anti allergic effect might be due to this component. 8 
Although, many studies had been conducted to complement the conventional treatment in AR, 
all of these studies used different type of honey and different routes of administration.9,10 This 
is the first study to the best of our knowledge that use tualang honey in the form of nasal spray.  
 
3.5 METHODOLOGY 
Study subjects 
The study protocol was approved by Medical Research and Ethic Committee of National 
Medical Research Registry (NMRR) Malaysia [NMRR-1-987-25579 (IIR)]. Patients were 
recruited from our Otolaryngology- Head & Neck Surgery clinic from November 2015 until 
July 2016. Those who were 18 years old and above, moderate to severe persistent AR with 
positive skin prick test (SPT) were included in the study. Patients with known allergy to honey, 
with multiple comorbid conditions such as chronic obstructive pulmonary disease, diabetes 
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mellitus and ischaemic heart disease as well as those who were pregnant and had undergone 
nasal surgery before were excluded. The patients’ demographic data and clinical history were 
recorded in the patient’s profoma. All patients underwent skin prick test (SPT) using ALK-
Abello skin prick test kit. They were tested for 11 allergens with positive and negative control. 
The allergens were Blomia tropicalis (house dust mite), Dermatophagoides pteronyssinus 
(house dust mite), Dermatophagoides farinae (house dust mite), Felis domesticus (cat), chicken 
meat, shrimp, egg white, egg yolk, cow’s milk, peanut, Apis millefera (honey bee), histamine 
(positive control), saline solution (negative control). SPT is positive in the presence of wheal 
of 2 mm  more than negative control after 15 minutes. 
 
Study design and randomization 
This was a randomized control trial study. With simple randomization technique, 15 subjects 
were enrolled in each control and trial groups. During randomization, the patients were given 
1 sealed envelope with a piece of paper written number 1 or 2. Those who received number 1 
were recruited into a control group and number 2 were trial group.  
 
Study intervention 
According to ARIA guidelines, all patients were already treated with standard treatment which 
were topical intranasal corticosteroid two puffs daily and oral antihistamine 10 mg daily. The 
trial group received additional adjunctive topical honey nasal spray 2 puffs at night. The 
treatment duration was for 6 weeks. The correct nasal spray technique was taught at the 
beginning of the study. They were instructed to use intranasal corticosteroid in the morning 
and honey nasal spray at night. Trial subjects were given a product brochure which consists of 
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brief information of topical honey nasal spray, its content and indication as well as usage and 
storage instructions. To ensure compliance, a diary to record date using honey nasal spray and 
any side effects were given. 
Interventional product 
The honey nasal spray was prepared in a laboratory at AMDI, Bertam. The source of tualang 
honey is from Federal Agricultural Marketing Authority (FAMA), Ministry of Agriculture & 
Agro-Based Industry Malaysia. Few processes involved in the production of honey nasal spray 
such as the formulation are sterilized using filter unit, which remove traces of fine particles in 
the solution. Seventhy five percent of honey is mixed in sterile distilled water. Subsequently, 
the PET bottles were exposed to UV-light for at least 2 hours, in order to disinfect the 
microorganisms on the surface of the bottles. Once the sterilization process is done, the filtered-
honey is aliquot into the bottles and ready to be distributed to patients (Figure 1). 
 
Figure 1: Honey nasal spray in 120 millilitre PET bottle. 
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Evaluation 
The symptoms were evaluated using a validated Malay-version Sinonasal Outcome Test-22 
(SNOT-22) questionnaire. The score was recorded at the beginning of the study (week 0) and 
repeated at the 2nd and 6th weeks of the study. Out of 22 questions, we highlighted the total 
score and 3 most common symptoms in AR which were nasal blockage, rhinorrhea and 
sneezing. The scoring is done by asking the subjects to rate the severity of symptoms with 
Linkert scale of five where 1 (means no problem) to 5 (means the most problematic). In 
addition, total serum IgE levels were done for all patients to objectively measure the outcome. 
Blood was taken for total serum IgE at the beginning (week 0) and at the end of the study (week 
6). 
 
Data analysis 
All the measured outcomes were analysed using repeated measure ANOVA to determine the 
significance of differences in total symptoms score and individual symptoms score between 
control and trial group at 0, 2nd and 6th week of study. 
 
 
 
 
 
 
14 
 
3.5 RESULT 
Thirty AR patients were recruited in this study. All were classified as moderate to severe 
persistent AR according to ARIA guideline and had a positive skin prick test to aeroallergens. 
They were randomly and equally divided into control and trial group. The mean age of patients 
was 32.2 years with an average of 33.7 years old for control and 30.8 years old for trial group. 
Eighteen were female, 10 of them were in trial group. The majority of the patient population 
were Malay (80%) followed by Chinese (16%) and Indian (4%). 
Repeated measured ANOVA was done to evaluate the measured outcome between each group 
at baseline, 2nd and 6th weeks of the study period. All scores in the SNOT-22 questionnaire 
were measured using survey score of Linkert scale of five whereby 1 (means no problem) to 5 
(means the most problematic). Out of 3 nasal symptoms that we assessed, nasal blockage is the 
most common complaint with mean score 3, followed by sneezing (mean score 2.9) and 
rhinorrhea (mean score 2.8).  
Table 1 shows significant improvement seen in mean symptoms score of all measured 
outcomes at the end of the study. In both groups, rhinorrhea showed early significant 
improvement (by 2nd week) meanwhile sneezing showed improvement only at the end of the 
study.  At the end of the study, there was an improvement of the mean total symptom score as 
well as the total serum IgE level in both control and trial groups. However, when comparing 
the overall mean score in between control and trial groups, there was no significant difference 
observed. This suggests that both groups had improvement of symptoms after treatment either 
with standard treatment only or with adjunctive honey nasal spray (Table 2).  
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Table 3 shows that both groups had improvement of estimated marginal means score of all 
parameters at the end of study and the improvement seen more in rhinorrhea and sneezing 
parameter as demonstrate by postitive mean different (MD). 
Table 1. Comparison of the improvement of the mean symptom score of the 3 symptoms 
of AR, Total SNOT-22 score and total serum IgE level in control and trial groups (based 
on time effect). 
Symptoms Week 
Control Trial 
mean difference 
(95% CI) 
p-value 
mean difference 
(95% CI) 
p- 
value 
Nasal blockage 0-6 1.33 (0.55, 2.11) 0.001 1.53 (0.41, 2.65) 0.007 
Rhinorrhea 0-6 1.00 (0.47,1.53) 0.000 1.33(0.28, 2.38) 0.012 
Sneezing 0-6 1.07 (0.57,1.56) <0.001 1.67 (0.55, 2.78) 0.030 
Total SNOT-22 0-6 9.73 (1.51, 17.96) 0.019 17.40 (3.59, 31.21) 0.012 
Total serum IgE 0-6 33.59(5.77,61.40) 0.021 103.58(7.13,200.03) 0.037 
 
Table 2. Comparison of mean difference of symptom score and total serum IgE level 
between control and trial groups at 6th week. 
Symptoms Comparison 
Mean difference (95% CI) p-value 
Nasal blockage control-trial -0.11 (-1.14, 0.91) 0.826 
Rhinorrhea control-trial 0.40 (-0.47,1.27) 0.356 
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Sneezing control-trial 0.31(-0.41, 1.03) 0.383 
Total SNOT-22 control-trial -11.84 (-27.68, 3.99) 0.137 
Total serum 
IgE control-trial 
-171.097 (-440.357, 98.164) 0.204 
 
Table 3 : Comparison of score among control and trial groups based on time (Time-
treatment interaction) 
Symptoms Time Comparison Mean Mean different  
( 95% CI) 
p-value 
Nasal blockage 0 weeks Control 2.93 -0.133 
(-1.143,1.16) 
0.834 
Trial 3.07 
2nd weeks Control 2.07 -0.27 
(-1.38,0.85) 
0.628 
Trial 2.33 
6th weeks Control 1.60 0.07 
(-0.95,1.08) 
0.894 
Trial 1.53 
Rhinorrhea 0 weeks Control 2.53 -0.53 
(-1.48,0.41) 
0.257 
Trial 3.07 
2nd weeks Control 1.80 -0.47 
(-1.35,0.42) 
0.290 
Trial 2.27 
6th weeks Control 1.50 -0.20 
(-1.26,0.86) 
0.703 
Trial 1.73 
Sneezing 0 weeks Control 2.67 -0.53 
(-1.38,0.31) 
0.207 
Trial 3.20 
17 
 
2nd weeks Control 2.00 -0.47 
(-1.46,0.53) 
0.346 
Trial 2.47 
6th weeks Control 1.60 0.067 
(-0.77,0.91) 
0.872 
Trial 1.53 
Total SNOT-22 0 weeks Control 29.93 -15.40 
(32.69,1.89) 
0.079 
Trial 45.33 
2nd weeks Control 24.33 -12.40 
(-29.29,4.49) 
0.144 
Trial 36.73 
6th weeks Control 20.20 -7.73 
(-24.26,8.79) 
0.346 
Trial 27.93 
Serum IgE 0 weeks Control 285.97 -206.09 
(501.02,88.83) 
0.163 
Trial 492.06 
6th weeks Control 252.38 -136.10 
(-386.34,114.14) 
0.275 
Trial 388.48 
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3.6 DISCUSSION 
Sinonasal Outcome Test-22 (SNOT-22) questionnaire is an assessment tool commonly used to 
evaluate the quality of life in patients with chronic rhinosinusitis. The SNOT-22 questionnaire 
has the advantage of combining issues which are specific of sinonasal disease with general 
health issues, which may be assessed alone or together.11 In addition, it also has been shown to 
be an accurate assessment tool in the evaluation of patients with allergic rhinitis.12 As all of our 
patients communicate using Malay language, we use the Malay validated Sinonasal Outcome 
Test-22 (SNOT-22) questionnaire in our study in order to give an accurate assessment of the 
treatment outcome.13   We focus on the three most common symptoms in AR which were nasal 
blockage, rhinorrhea and sneezing as these symptoms have been shown to be the most 
troublesome among allergic rhinitis sufferers.14 
Our study showed significant improvement of total symptoms score and total serum Ig E level 
in both groups. However, trial group who received honey nasal spray exhibited more consistent 
alleviation of symptoms (nasal blockage, sneezing and rhinorrhoea) as well as reduction in 
total serum Ig E level as shown by the estimated means total symptoms score throughout the 
study period from week 0 to week 6.  This demonstrates that the tualang honey nasal spray has 
adjunctive beneficial effect in alleviating the symptoms of AR. The exact mechanism of action 
(MOA) of honey is not yet known. The anti-inflammatory and antioxidant properties of honey 
most probably due to its bioactive substances of phenol and flavonoids.15 Mohamed et al. 16  
have shown that Malaysian Tualang honey contains highly phenolic and flavonoid  compounds 
that possess relatively good antioxidant activity. Flavonoid exert its anti-inflammatory effect 
by its action on the enzymes (kinase and thyrosine) involved in the inflammatory processes. It 
competitively binds to ATP  at catalytic sites of the enzymes, thus leads to inactivation of signal 
transduction in the immune cascade.17 The anti-inflammatory effect of honey was well 
19 
 
demonstrated by Kamaruzzaman et al.18 This study uses aerosolized tualang honey to treat 
ovalbumin induce asthma in rabbits.  Histopathological examinations of rabbit lungs showed  
reduction in the mucus secreting goblet cell hyperplasia of respiratory epithelium after 5 days 
of honey nebulizer. 
The more consistent reduction in total serum IgE level in trial group as compared to the control 
group (showing a slight increase in estimated marginal mean at 6th week) demonstrates the anti 
allergic property of honey. Ishikawa et al19 found that honey bee exert an anti-allergic effect 
by inhibiting the Fc immune-globulin E receptor that inhibits binding of IgE to mast cell and 
thus prevents mast cell degranulation. 
The other possible mechanism of action of tualang honey is directly by its local effect on the 
nasal mucosa. Thick and sticky consistency of tualang honey will form a layer acting as 
mucosal barrier in preventing the attachment of aero-allergens to the nasal mucosa. Thus, this 
will reduce inflammatory reactions by reducing the number of allergens being presented to the 
antigen representing cells (APC). This is the most probable reason for the symptoms reduction 
seen in our patients who received the topical honey nasal spray. 
Since ancient time, honey has been widely used as food supplement and natural remedies for 
various chronic illnesses. Due to its beneficial effect on various diseases, the disadvantage of 
honey either by ingestion, inhalation or topical use is less debated. The only myths on the 
disadvantages or limitation of honey is its use in diabetics. Most believed that it can worsen 
blood sugar level in diabetics. However, the study showed that honey, especially tualang, has 
intermediate glycemic index and help in reducing blood sugar level when use in combination 
with oral hypoglycemic agents.20,21 
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Pharmacologcally, oral ingestion of honey  has more systemic bioavailabity and causea more 
systemic effect. Vice versa in our study, whereby we found that, a significant reduction of the 
total serum IgE level at the end of study in trial group. The clinical improvement of nasal 
symptoms, however, are less significant.  This is the uniqueness of honey and we postulated 
that topical honey in this study exerts more  systemic effects. The possible mechanism of action 
probably by absorption from nasal mucosa. However, the exact MOA is still not well 
understood and beyond this study. 
Apart from its systemic beneficial effect, topical honey does have local side effect mainly local 
discomfort and excessive rhinorrhea immediately after use. 
 The study is not without limitations. It is a single centre study and the small sample size may 
not represent the whole population.  As this study is only for short duration, the long term effect 
of the topical honey nasal spray as well as any residual effect after its discontinuation remained 
to be seen. It is a possibility that there might be more consistent reduction in total symptoms 
score and IgE level by the continuous use of honey nasal spray and a longer duration of study 
is warranted to determine its long term efficacy.  
Conclusions 
The topical honey nasal spray has beneficial effect as an adjunct treatment in moderate to 
severe persistent allergic rhinitis by acting as a protective mucous layer in reducing the 
attachment of allergens to the nasal mucosa. The anti-inflammatory and anti-allergy property 
is yet to be proven and requires further study. 
 
All authors declared no conflict of interest. 
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